Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NGM Biopharmaceuticals Inc (NGM)
NASDAQ:NGM
Holding NGM?
Track your performance easily
NGM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.60 - $4.69
Previous Close$1.59
Volume357.15K
Average Volume (3M)1.48M
Market Cap
$132.71M
Enterprise Value-$31.96M
Total Cash (Recent Filing)$166.04M
Total Debt (Recent Filing)$1.38M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
May 02, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding83,462,408
10 Day Avg. Volume1,301,663
30 Day Avg. Volume1,475,508
Standard Deviation0.22
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.78
Price to Sales (P/S)7.31
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.43
Enterprise Value/Gross Profit-0.58
Enterprise Value/Ebitda0.21
Forecast
1Y Price Target
$1.55Price Target Upside-2.52% Downside
Rating ConsensusHold
Number of Analyst Covering4
NGM Biopharmaceuticals News
PremiumCompany Announcements
NGM Biopharmaceuticals’ Strategic Merger and Corporate Transformation
PremiumPress Releases
NGM Bio Announces Closing of Tender Offer
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NGM FAQ
What was NGM Biopharmaceuticals Inc’s price range in the past 12 months?
NGM Biopharmaceuticals Inc lowest stock price was $0.60 and its highest was $4.69 in the past 12 months.
What is NGM Biopharmaceuticals Inc’s market cap?
Currently, no data Available
When is NGM Biopharmaceuticals Inc’s upcoming earnings report date?
NGM Biopharmaceuticals Inc’s upcoming earnings report date is May 02, 2024 which is 202 days ago.
How were NGM Biopharmaceuticals Inc’s earnings last quarter?
NGM Biopharmaceuticals Inc released its earnings results on Mar 11, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.393 by $0.063.
Is NGM Biopharmaceuticals Inc overvalued?
According to Wall Street analysts NGM Biopharmaceuticals Inc’s price is currently Overvalued.
Does NGM Biopharmaceuticals Inc pay dividends?
NGM Biopharmaceuticals Inc does not currently pay dividends.
What is NGM Biopharmaceuticals Inc’s EPS estimate?
NGM Biopharmaceuticals Inc’s EPS estimate is -$0.36.
How many shares outstanding does NGM Biopharmaceuticals Inc have?
NGM Biopharmaceuticals Inc has 83,462,410 shares outstanding.
What happened to NGM Biopharmaceuticals Inc’s price movement after its last earnings report?
NGM Biopharmaceuticals Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.393. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NGM Biopharmaceuticals Inc?
Among the largest hedge funds holding NGM Biopharmaceuticals Inc’s share is Caxton Associates LP. It holds NGM Biopharmaceuticals Inc’s shares valued at N/A.
---
NGM Biopharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.55 (-2.52% Downside)
$1.55 (-2.52% Downside)
Blogger Sentiment
Bullish
NGM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 32.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▼ 17.4%
Last 30 Days ▼ 17.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.37%
12-Months-Change
Fundamentals
Return on Equity
-69.76%
Trailing 12-Months
Asset Growth
-45.07%
Trailing 12-Months
Company Description
NGM Biopharmaceuticals Inc
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.
---
NGM Stock 12 Month Forecast
Average Price Target
$1.55
▼(-2.52% Downside)
Technical Analysis
---